Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...

Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...

In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

The gene therapy delandistrogene moxeparvovec-rokl showed clinically meaningful benefits and disease stabilization at 2 years ...

Analysts at William Blair boosted their FY2024 earnings per share estimates for shares of Sarepta Therapeutics in a research ...

Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...